Fiche publication
Date publication
janvier 2026
Journal
Gynecologie, obstetrique, fertilite & senologie
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVALLAND Christine
Tous les auteurs :
Bris DL, Devalland C, Puyraveau M, Bourgoin C, Bouvier E, Gay C
Lien Pubmed
Résumé
Objective : To analyze the clinical and cyto-histological evolution of Genitourinary Syndrome of Menopause (GSM) with the use of fractional carbon dioxide laser. Methods : We conducted a prospective clinical trial at the Hôpital Nord Franche Comté, Trévenans, France, over a period of 19 months from 2022 to 2023. The patients enrolled were women over 40 years old, postmenopausal with vaginal symptoms of GSM. The primary outcome was the comparison of the clinical symptom intensity score before and after the three laser sessions. The secondary outcomes were the evolution of GSM with laser treatment through a clinical score, a medical score, the assessment of the sexual quality of life, the study of the cytological and histological effects of the laser, and its side effects. Results : Among the 75 patients enrolled, 68 have been studied. There was a significant improvement of all the symptoms, the medical score and the sexual quality of life after three laser sessions (p<0,01). In cytology, there was an improvement in the vaginal maturation value with an increase in superficial cells and a decrease in basal cells (p<0,01). Histologically, there was an increase in the thickness of the epithelium (p<0,01), the size of the epithelial cells (p=0,01), and the glycogen (p<0,01), and a decrease in the thickness of the basal layers (p<0,01). Conclusion : Fractional carbon dioxide laser improves symptoms of GSM, sexual quality of life and restores the characteristics of the vaginal epithelium with effects still present six months after.
Mots clés
Genitourinary Syndrome of Menopause, Syndrome Génito-Urinaire de la Ménopause, atrophie vulvo-vaginale, cancer, fractional carbon dioxide laser, laser CO(2) fractionné, menopause, ménopause, vulvovaginal atrophy
Référence
Gynecol Obstet Fertil Senol. 2026 01 21;:
